Rapid Readout: Expert Perspectives on Multiple Sclerosis - Data from the 8th Joint ACTRIMS-ECTRIMS Meeting 2020 : Episode 11

Video

November 24, 2020

Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

Author(s):

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD

EP: 1.Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

EP: 2.OLKIOS: Looking at Ofatumumab’s Continued Efficacy

EP: 3.OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

EP: 4.Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

EP: 5.Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

EP: 6.Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

EP: 7.OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

EP: 8.OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

EP: 9.Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

EP: 10.Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

EP: 11.Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

EP: 12.Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

EP: 13.CLARITY Extension Trial: Disability Improvement With Cladribine

EP: 14.COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

EP: 15.Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

Related Videos

Kathleen Costello, CRNP, MSCN

Christian Cordano, MD, PhD

Jack P. Antel, M D

Sarah Levy, PhD

Enrique Alvarez, MD, PhD

Ceren Tozlu, PhD

Cristin Welle, PhD

Related Content

Related Content

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.